Kathleen Moore to Clinical Trials as Topic
This is a "connection" page, showing publications Kathleen Moore has written about Clinical Trials as Topic.
Connection Strength
2.086
-
Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 02 26; 21(3):22.
Score: 0.569
-
Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecol Oncol. 2017 04; 145(1):32-36.
Score: 0.491
-
Research: An event or an environment? Gynecol Oncol. 2014 Sep; 134(3):441-2.
Score: 0.417
-
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Dec; 191:249-258.
Score: 0.211
-
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol. 2020 07; 158(1):16-24.
Score: 0.154
-
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018 04; 149(1):214-220.
Score: 0.132
-
Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016 Jan; 140(1):161-6.
Score: 0.113